VHL-based EP-300 selective degrader (Pfizer)

N/A

Report date: 2025/06/11 10:53:13
NME

Base Information

Drug NameVHL-based EP-300 selective degrader (Pfizer)
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionHistone acetyltransferase p300 inhibitors
TargetsHistone acetyltransferase p300
Therapy Area/IndicationsHematologic NeoplasmsMultiple MyelomaLymphoma, Large B-Cell, Diffuse +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsMultiple MyelomaLymphoma, Large B-Cell, Diffuse +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A